![](https://d3ilqtpdwi981i.cloudfront.net/d2I2enheGGc3pTdyhgqihQW830s=/425x550/smart/https://bepress-attached-resources.s3.amazonaws.com/uploads/50/52/0e/50520e34-4264-41bb-941e-68cddc0523c7/file.jpg)
Article
Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
Blood
(2018)
Disciplines
Publication Date
November 21, 2018
DOI
10.1182/blood-2018-99-110617
Citation Information
Tycel J. Phillips, Stephen D. Smith, Wojciech Jurczak, Tadeusz Robak, et al.. "Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)" Blood Vol. 132 (2018) p. 4144 - 4144 Available at: http://works.bepress.com/john-pagel/297/